Brokerages expect Acadia Healthcare Company, Inc. (NASDAQ:ACHC) to post sales of $559.56 million for the current quarter, according to Zacks. Three analysts have issued estimates for Acadia Healthcare’s earnings, with the highest sales estimate coming in at $562.70 million and the lowest estimate coming in at $556.16 million. Acadia Healthcare reported sales of $750.31 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 25.4%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 3rd.
On average, analysts expect that Acadia Healthcare will report full-year sales of $2.26 billion for the current year, with estimates ranging from $2.25 billion to $2.27 billion. For the next year, analysts expect that the firm will report sales of $2.43 billion, with estimates ranging from $2.40 billion to $2.45 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Acadia Healthcare.
Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings results on Wednesday, April 28th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.02. Acadia Healthcare had a net margin of 3.19% and a return on equity of 7.55%.
Shares of NASDAQ:ACHC traded up $0.19 during trading on Thursday, reaching $62.28. The company had a trading volume of 311,041 shares, compared to its average volume of 575,646. The firm’s fifty day moving average is $59.27 and its 200 day moving average is $50.15. The firm has a market capitalization of $5.57 billion, a PE ratio of 54.95, a price-to-earnings-growth ratio of 1.49 and a beta of 1.49. Acadia Healthcare has a twelve month low of $23.01 and a twelve month high of $63.06. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.26 and a current ratio of 1.26.
In other news, Director Reeve B. Waud sold 109,443 shares of the business’s stock in a transaction that occurred on Friday, March 12th. The shares were sold at an average price of $59.12, for a total transaction of $6,470,270.16. Following the sale, the director now owns 25,765 shares in the company, valued at $1,523,226.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. CWM LLC increased its stake in Acadia Healthcare by 241.4% in the 1st quarter. CWM LLC now owns 495 shares of the company’s stock valued at $28,000 after buying an additional 350 shares during the period. Nisa Investment Advisors LLC acquired a new position in Acadia Healthcare in the 4th quarter valued at approximately $35,000. Eudaimonia Partners LLC acquired a new position in Acadia Healthcare in the 3rd quarter valued at approximately $92,000. Exane Derivatives increased its stake in Acadia Healthcare by 66,000.0% in the 1st quarter. Exane Derivatives now owns 2,644 shares of the company’s stock valued at $151,000 after buying an additional 2,640 shares during the period. Finally, CLARET ASSET MANAGEMENT Corp acquired a new position in Acadia Healthcare in the 1st quarter valued at approximately $205,000.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.